Brief: Qyuns Therapeutics Announces Exclusive License Agreement With F. Hoffmann-La Roche
28/10/2025 12:32
Oct 28 (Reuters) - Qyuns Therapeutics Co Ltd 2509.HK: ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH F. HOFFMANN-LA ROCHE TO RECEIVE $75 MILLION UPFRONT AND UP TO $995 MILLION IN MILESTONES GRANTS ROCHE GLOBAL EXCLUSIVE RIGHT TO DEVELOP, OTHERS QX031N Further company coverage: 2509.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Qyuns Therapeutics
See all newsBrief: QYUNS Therapeutics Posts HY Adjusted Profit Of RMB202.5 MLN
Brief: Qyuns Therapeutics Says Qx027n Obtains Two Clinical Trial Approvals For Copd, Chronic Rhinosinusitis
Brief: Qyuns Therapeutics Says Saifu Juli To Buy 34% Of Cellularforce For RMB86.02 Million
Brief: Qyuns Therapeutics Repurchases 3.43 Million Shares As Treasury Shares From Nov 6, 2025 To June 9
Brief: Qyuns Therapeutics Co Receives Milestone Payment From Roche